重组融合蛋白免疫可保护小鼠抵御幽门螺杆菌感染
研究将幽门螺杆菌FliD、UreB、VacA和CagL抗原片段融合表达为重组蛋白rFUVL,联合CpG ODN、Addavax或霍乱毒素B亚单位三种佐剂免疫小鼠,与PBS对照组相比,免疫鼠细胞回忆应答及抗原特异性IgG2a、IgG1和胃IgA抗体滴度显著升高,胃内细菌载量降低约三个数量级。
要点
- rFUVL联合三种佐剂免疫小鼠,抗原特异性抗体和细胞回忆应答显著高于PBS对照组。
- rFUVL免疫小鼠胃内细菌载量较对照组降低约三个数量级。
- 作者认为佐剂化rFUVL可能是控制幽门螺杆菌感染的有前景疫苗候选。
核心结论
- 佐剂化rFUVL可能是控制幽门螺杆菌感染的有前景疫苗候选。
研究设计与样本
- 将编码幽门螺杆菌FliD、UreB、VacA和CagL抗原片段的嵌合基因在细菌中表达,所得融合蛋白rFUVL联合CpG ODN、Addavax或霍乱毒素B亚单位三种佐剂免疫小鼠,评估体液免疫、细胞免疫及抗感染保护作用。
主要发现
- 与接受PBS的对照组相比,免疫小鼠细胞回忆应答及抗原特异性IgG2a、IgG1和胃IgA抗体滴度显著更高。
- rFUVL免疫小鼠胃内细菌载量降低约三个数量级。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
More than 50% of the world's population is infected with the bacterium Helicobacter pylori. If left untreated, infection with H. pylori can cause chronic gastritis and peptic ulcer disease, which may progress into gastric cancer. Owing to the limited efficacy of anti-H. pylori antibiotic therapy in clinical practice, the development of a protective vaccine to combat this pathogen has been a tempting goal for several years. In this study, a chimeric gene coding for the antigenic parts of H. pylori FliD, UreB, VacA, and CagL was generated and expressed in bacteria and the potential of the resulting fusion protein (rFUVL) to induce humoral and cellular immune responses and to provide protection against H. pylori infection was evaluated in mice. Three different immunization adjuvants were tested along with rFUVL: CpG oligodeoxynucleotides (CpG ODN), Addavax, and Cholera toxin subunit B. Compared to the control group that had received PBS, vaccinated mice showed significantly higher cellular recall responses and antigen-specific IgG2a, IgG1, and gastric IgA antibody titers. Importantly, rFUVL immunized mice exhibited a reduction of about three orders of magnitude in their stomach bacterial loads. Thus, adjuvanted rFUVL might be considered as a promising vaccine candidate for the control of H. pylori infection.
引用
- Ghasemi A, Mohammad N, Mautner J, et al. Immunization with a recombinant fusion protein protects mice against Helicobacter pylori infection. Vaccine. 2018. PMID: 30041879. doi:10.1016/j.vaccine.2018.07.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。